Inhalation therapy containing manuka honey, amikacin shows promise for respiratory infections

September 15, 2022

2 minutes to read

We were unable to process your request. Please try again later. If this issue still occurs, please contact

The combination of manuka honey and the antibiotic amikacin in a laboratory nebulization formulation was effective in inhibiting Mycobacterium abscess and drug-resistant clinical isolates in patients with cystic fibrosis or bronchiectasis.

“So far, the treatment Mycobacterium abscess Pneumonia can be a problem due to its drug-resistant nature. The diversity of antibiotics needed to fight infection leads to serious side effects,” Victoria C. Nolan, MsAnd the A PhD researcher at Aston University in Birmingham, UK, said in a related press release. “However, the use of this potential treatment combining amikacin honey and manuka honey shows great promise as an improved treatment for these horrible lung infections.”

Source: Adobe Stock.

Previous research has shown that Manuka honey has a wide range of antimicrobial activity, according to the release.

The researchers collected samples from M. abscessAnd the who usually infects Patients with cystic fibrosis or bronchiectasisAnd the of 16 patients with cystic fibrosis who evaluated manuka honey with amikacin (Insmed) to determine the dose needed to kill the bacteria. Using a laboratory-based lung model and a nebulizer, the researchers sprayed manuka honey with amikacin.

The results are published in microbiologyshowed that the highest concentration (0.476 g/ml-1) out of all four strengths of tested manuka honey M. abscess. In addition, researchers have proven that the highest concentration is bactericidal. Compared to no manuka honey treatment, the next lowest concentration of manuka honey is (0.238 g/ml-1) reduces bacterial growth but does not show a bactericidal effect.

Additionally, manuka honey blend vaporized at 0.37g/ml-1 Amikacin 1.6 mg/ml-1 prevent growth M. abscess. This lower dose of amikacin may result in fewer life-changing adverse events, the researchers wrote.

To assess antimicrobial activity, the researchers examined M. abscess samples versus the four manuka honey samples and observed varied activity for all isolates with a minimum inhibitory concentration of 0.476 g/ml-1 or less, depending on the results.

“The use of amikacin honey and manuka honey inhalation therapy shows promising results as an improved treatment for M. abscess Lung infections, which can lead to an increase in successful treatment outcomes and a reduced burden on the patient from drug-related side effects,” the researchers wrote.

More research is warranted, according to the researchers.

“I am pleased with the outcome of this research as it paves the way for future trials, and we hope that with funding we can move towards clinical trials that could lead to a change in the strategy for treating this debilitating infection,” Jonathan Cox MD, Senior Lecturer in Microbiology in the School of Biological Sciences at Aston University, said in the statement.